636 related articles for article (PubMed ID: 2456487)
1. Immunocytochemical studies on the basal ganglia and substantia nigra in Parkinson's disease and Huntington's chorea.
Waters CM; Peck R; Rossor M; Reynolds GP; Hunt SP
Neuroscience; 1988 May; 25(2):419-38. PubMed ID: 2456487
[TBL] [Abstract][Full Text] [Related]
2. Immunocytochemical studies of substance P and Met-enkephalin in the basal ganglia and substantia nigra in Huntington's, Parkinson's and Alzheimer's diseases.
Grafe MR; Forno LS; Eng LF
J Neuropathol Exp Neurol; 1985 Jan; 44(1):47-59. PubMed ID: 2578185
[TBL] [Abstract][Full Text] [Related]
3. Microtopography of D1 dopaminergic binding sites in the human substantia nigra: an autoradiographic study.
Thibaut F; Hirsch EC; Raisman R; Javoy-Agid F; Agid Y
Neuroscience; 1990; 37(2):387-98. PubMed ID: 1983469
[TBL] [Abstract][Full Text] [Related]
4. Immunocytochemical studies of substance P and leucine-enkephalin in Huntington's disease.
Marshall PE; Landis DM; Zalneraitis EL
Brain Res; 1983 Dec; 289(1-2):11-26. PubMed ID: 6198034
[TBL] [Abstract][Full Text] [Related]
5. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease.
Kordower JH; Olanow CW; Dodiya HB; Chu Y; Beach TG; Adler CH; Halliday GM; Bartus RT
Brain; 2013 Aug; 136(Pt 8):2419-31. PubMed ID: 23884810
[TBL] [Abstract][Full Text] [Related]
6. Correlation of dopaminergic terminal dysfunction and microstructural abnormalities of the basal ganglia and the olfactory tract in Parkinson's disease.
Scherfler C; Esterhammer R; Nocker M; Mahlknecht P; Stockner H; Warwitz B; Spielberger S; Pinter B; Donnemiller E; Decristoforo C; Virgolini I; Schocke M; Poewe W; Seppi K
Brain; 2013 Oct; 136(Pt 10):3028-37. PubMed ID: 24014521
[TBL] [Abstract][Full Text] [Related]
7. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneity of melanized neurons expressing neurotensin receptor messenger RNA in the substantia nigra and the nucleus paranigralis of control and Parkinson's disease brain.
Yamada M; Yamada M; Richelson E
Neuroscience; 1995 Jan; 64(2):405-17. PubMed ID: 7700529
[TBL] [Abstract][Full Text] [Related]
9. Pathological changes in dendrites of substantia nigra neurons in Parkinson's disease: a Golgi study.
Patt S; Gertz HJ; Gerhard L; Cervós-Navarro J
Histol Histopathol; 1991 Jul; 6(3):373-80. PubMed ID: 1725760
[TBL] [Abstract][Full Text] [Related]
10. Striato-nigral dynorphin and substance P pathways in the rat. I. Biochemical and immunohistochemical studies.
Christensson-Nylander I; Herrera-Marschitz M; Staines W; Hökfelt T; Terenius L; Ungerstedt U; Cuello C; Oertel WH; Goldstein M
Exp Brain Res; 1986; 64(1):169-92. PubMed ID: 2429858
[TBL] [Abstract][Full Text] [Related]
11. Loss of non-phosphorylated neurofilament immunoreactivity, with preservation of tyrosine hydroxylase, in surviving substantia nigra neurons in Parkinson's disease.
Gai WP; Vickers JC; Blumbergs PC; Blessing WW
J Neurol Neurosurg Psychiatry; 1994 Sep; 57(9):1039-46. PubMed ID: 7916375
[TBL] [Abstract][Full Text] [Related]
12. An immunohistochemical study of the acute and long-term effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset.
Waters CM; Hunt SP; Jenner P; Marsden CD
Neuroscience; 1987 Dec; 23(3):1025-39. PubMed ID: 2893993
[TBL] [Abstract][Full Text] [Related]
13. Increased M-calpain expression in the mesencephalon of patients with Parkinson's disease but not in other neurodegenerative disorders involving the mesencephalon: a role in nerve cell death?
Mouatt-Prigent A; Karlsson JO; Agid Y; Hirsch EC
Neuroscience; 1996 Aug; 73(4):979-87. PubMed ID: 8809817
[TBL] [Abstract][Full Text] [Related]
14. Subdivisional involvement of nigrostriatal loop in idiopathic Parkinson's disease and striatonigral degeneration.
Goto S; Hirano A; Matsumoto S
Ann Neurol; 1989 Dec; 26(6):766-70. PubMed ID: 2557795
[TBL] [Abstract][Full Text] [Related]
15. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease.
Glass M; Dragunow M; Faull RL
Neuroscience; 2000; 97(3):505-19. PubMed ID: 10828533
[TBL] [Abstract][Full Text] [Related]
16. Serotonin-1 receptor binding sites in the human basal ganglia are decreased in Huntington's chorea but not in Parkinson's disease: a quantitative in vitro autoradiography study.
Waeber C; Palacios JM
Neuroscience; 1989; 32(2):337-47. PubMed ID: 2531301
[TBL] [Abstract][Full Text] [Related]
17. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease.
Damier P; Hirsch EC; Agid Y; Graybiel AM
Brain; 1999 Aug; 122 ( Pt 8)():1437-48. PubMed ID: 10430830
[TBL] [Abstract][Full Text] [Related]
18. Peptides derived from prodynorphin are decreased in basal ganglia of Huntington's disease brains.
Dawbarn D; Zamir N; Waters CM; Hunt SP; Emson PC; Brownstein MJ
Brain Res; 1986 Apr; 372(1):155-8. PubMed ID: 2871898
[TBL] [Abstract][Full Text] [Related]
19. The GABA and substance P input to dopaminergic neurones in the substantia nigra of the rat.
Bolam JP; Smith Y
Brain Res; 1990 Oct; 529(1-2):57-78. PubMed ID: 1704287
[TBL] [Abstract][Full Text] [Related]
20. Neuropathology of the substantia nigra.
Gibb WR
Eur Neurol; 1991; 31 Suppl 1():48-59. PubMed ID: 1830274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
